Categories Earnings, Health Care
Earnings Summary: Highlights of Charles River Laboratories’ Q3 2023 results
Pharma company Charles River Laboratories International, Inc. (NYSE: CRL) on Wednesday reported financial results for the third quarter of 2023.
- Revenue was $1.03 billion in the September quarter, an increase of 3.8% from $989.2 million last year
- Organic revenue rose 4.1%, driven primarily by the Discovery and Safety Assessment and Research Models and Services businesses
- Third-quarter net income decreased 9.4% annually to $87.4 million; earnings per share were $1.69, down 10.1%
- Adjusted net income increased to $140.5 million or $2.72 per share from $134.7 million or $2.63 per share in Q3 2022
- The management expects revenues to grow between 2.5% and 3.5% in fiscal 2023
- Organic revenue is estimated to increase in the range of 5.5% to $6.5%
- The company is looking for full-year earnings in the range of $7.30 per share to $7.50 per share
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
